Laden…
cis-(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenyl-cyclopropanecarboxamide
Levomilnacipran is a selective serotonin-norepinephrine reuptake inhibitor (SNRI) used for the treatment of depression. It works by inhibiting the reuptake of serotonin and norepinephrine, which increases the availability of these neurotransmitters in the synaptic cleft. The substance has a moderate side effect profile and is frequently prescribed for major depression. Due to its pharmacological properties, it may have effects on the central nervous system and the cardiovascular system.
Class
Not clearly classified yet
Pharmacological context
Mechanism
NET inhibitor, SERT inhibitor
Short read on known pharmacology
Interactions
No curated pairs visible
Curated visible combinations
Risk theme
Interpret risks carefully
Condensed from structured notes
Translation in progress
The German version has more complete content. This English page is being expanded; safety-critical risk and interaction sections may still appear while translation continues.
Receptor Targets
Mechanism of Action
Levomilnacipran acts through the following pharmacological mechanisms:
Designations
IUPAC: cis-(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenyl-cyclopropanecarboxamide
Receptor Profile
Der Serotonintransporter (SERT/5-HTT) ist ein Natrium-abhängiger Monoamintransporter, der Serotonin aus dem synaptischen Spalt zurück in die präsynaptische Zelle transportiert. Er ist das primäre Ziel von SSRI und MDMA.
Der Noradrenalintransporter (NET) ist ein Monoamintransporter, der Noradrenalin aus dem synaptischen Spalt zurücktransportiert. Er wird von verschiedenen Stimulants und Antidepressiva beeinflusst.
Substance Fingerprint
Pharmacological profile based on receptor binding, mechanism of action, and substance class. Limited data — interpret profile with caution.
Synapedia Evidence
Effects & Pharmacology translation in progress
English prose is being expanded. The German version currently has more detail.
Reported range 40–120 mg
Total duration 24 hours
Oral
| Tier | Dosage |
|---|---|
| Light | 20 mg |
| Reported | 40–120 mg |
| Strong | max. 120 mg |
Oral
Onset
1–2 weeks
Peak
4–6 hours
Total duration
24 hours
Avoid uncertain dosage claims and do not infer numbers when data is unclear.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Summary
Mögliche Nebenwirkungen umfassen Übelkeit, Schwindel und Schlaflosigkeit.
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.